These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. FERM control of FAK function: implications for cancer therapy. Lim ST; Mikolon D; Stupack DG; Schlaepfer DD Cell Cycle; 2008 Aug; 7(15):2306-14. PubMed ID: 18677107 [TBL] [Abstract][Full Text] [Related]
4. Focal adhesion kinase as a cancer therapy target. Golubovskaya VM Anticancer Agents Med Chem; 2010 Dec; 10(10):735-41. PubMed ID: 21214510 [TBL] [Abstract][Full Text] [Related]
5. Focal adhesion kinase: a potential target in cancer therapy. van Nimwegen MJ; van de Water B Biochem Pharmacol; 2007 Mar; 73(5):597-609. PubMed ID: 16997283 [TBL] [Abstract][Full Text] [Related]
7. Development of focal adhesion kinase inhibitors in cancer therapy. Ma WW Anticancer Agents Med Chem; 2011 Sep; 11(7):638-42. PubMed ID: 21787276 [TBL] [Abstract][Full Text] [Related]
9. Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK). Lu Y; Sun H J Med Chem; 2020 Dec; 63(23):14382-14403. PubMed ID: 33058670 [TBL] [Abstract][Full Text] [Related]
10. FAK signaling in human cancer as a target for therapeutics. Lee BY; Timpson P; Horvath LG; Daly RJ Pharmacol Ther; 2015 Feb; 146():132-49. PubMed ID: 25316657 [TBL] [Abstract][Full Text] [Related]
11. The roles of nuclear focal adhesion kinase (FAK) on Cancer: a focused review. Zhou J; Yi Q; Tang L J Exp Clin Cancer Res; 2019 Jun; 38(1):250. PubMed ID: 31186061 [TBL] [Abstract][Full Text] [Related]
12. Focal adhesion kinase-An emerging viable target in cancer and development of focal adhesion kinase inhibitors. Chauhan A; Khan T Chem Biol Drug Des; 2021 Mar; 97(3):774-794. PubMed ID: 33191630 [TBL] [Abstract][Full Text] [Related]
13. Progress in researches about focal adhesion kinase in gastrointestinal tract. Hao HF; Naomoto Y; Bao XH; Watanabe N; Sakurama K; Noma K; Tomono Y; Fukazawa T; Shirakawa Y; Yamatsuji T; Matsuoka J; Takaoka M World J Gastroenterol; 2009 Dec; 15(47):5916-23. PubMed ID: 20014455 [TBL] [Abstract][Full Text] [Related]
14. High resolution crystal structure of the FAK FERM domain reveals new insights on the Druggability of tyrosine 397 and the Src SH3 binding site. Marlowe T; Dementiev A; Figel S; Rivera A; Flavin M; Cance W BMC Mol Cell Biol; 2019 May; 20(1):10. PubMed ID: 31109284 [TBL] [Abstract][Full Text] [Related]
15. Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders. Yang M; Xiang H; Luo G Biochem Pharmacol; 2024 Jun; 224():116246. PubMed ID: 38685282 [TBL] [Abstract][Full Text] [Related]
16. FERM domain promotes resveratrol-induced apoptosis in endothelial cells via inhibition of NO production. Lee HR; Kim J; Park J; Ahn S; Jeong E; Park H Biochem Biophys Res Commun; 2013 Nov; 441(4):891-6. PubMed ID: 24211585 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. Schultze A; Fiedler W Expert Opin Investig Drugs; 2010 Jun; 19(6):777-88. PubMed ID: 20465362 [TBL] [Abstract][Full Text] [Related]
18. Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy. Pang XJ; Liu XJ; Liu Y; Liu WB; Li YR; Yu GX; Tian XY; Zhang YB; Song J; Jin CY; Zhang SY Molecules; 2021 Jul; 26(14):. PubMed ID: 34299525 [TBL] [Abstract][Full Text] [Related]
19. The role of FAK in tumor metabolism and therapy. Zhang J; Hochwald SN Pharmacol Ther; 2014 May; 142(2):154-63. PubMed ID: 24333503 [TBL] [Abstract][Full Text] [Related]
20. FAK-targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials. Mohanty A; Pharaon RR; Nam A; Salgia S; Kulkarni P; Massarelli E Expert Opin Investig Drugs; 2020 Apr; 29(4):399-409. PubMed ID: 32178538 [No Abstract] [Full Text] [Related] [Next] [New Search]